去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效和安全性的系统性评价

Systematic Evaluation of Efficacy and Safety of Demethoxorubicin Combined with Cytarabine in the Treatment of Acute Myeloid Leukemia

目的:利用Meta分析的方法,对去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效和安全性情况进行系统性评价.方法:通过计算机检索文献资料数据库,查询关于去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效和安全性的文献资料,采用Revman5.3软件对文献资料进行系统性评价.结果:Meta分析结果显示,去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效较好[RR=0.76;95%CI(0.69,0.97),P<0.001];KPS评分较高[RR=-7.44;95%CI(-9.00,-5.88),P<0.001].针对并发症的亚组分析结果显示未显著增加发病率,白细胞下降[RR=1.13;95%CI(0.66,1.93),P=0.66];骨髓抑制[RR=1.06;95%CI(0.95,1.19),P=0.28];胃肠道反应[RR=1.05;95%CI(0.90,1.22),P=0.52];感染、发热[RR=0.95;95%CI(0.79,1.15),P=0.62].结论:去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效和安全性较好,值得临床推广应用.

objective:to evaluate the efficacy and safety of demethoxorubicin combined with cytarabine in the treatment of acute myeloid leukemia(AML)by means of meta-analysis.Methods:through the computer search of the literature database,the literature on the efficacy and safety of demethoxorubicin combined with cytarabine in the treatment of acute myeloid leukemia was inquired,and the literature was systematically evaluated by Revman5.3 software.Results:meta-analysis showed that demethoxorubicin combined with cytarabine was effective in the treatment of acute myeloid leukemia[RR=0.76;95%CI(0.69,0.97),P<0.001].KPS score was higher[RR=-7.44;95%CI(-9.00,-5.88),P<0.001].The results of the subgroup analysis of complications showed no significant increase in the incidence and decreased leucocyte[RR=1.13;95%CI(0.66,1.93),P=0.66].Myelosuppression[RR=1.06;95%CI(0.95,1.19),P=0.28];Gastrointestinal reactions[RR=1.05;95%CI(0.90,1.22),P=0.52];Infection and fever[RR=0.95;95%CI(0.79,1.15),P=0.62].Conclusion:demethoxorubicin combined with cytarabine is effective and safe in the treatment of acute myeloid leukemia.